Honor

   Drug submissions   

JYMed has successfully completed the registration and filing of five peptide APIs with China’s regulatory authorities, ten DMF filings with the U.S. FDA, one VMF filing with the U.S. FDA, and one MF filing with Health Canada. Additionally, the company has obtained a Certificate of Suitability (CEP) for Oxytocin API from the European Directorate for the Quality of Medicines (EDQM) and has submitted two DMF filings in South Korea.Among these achievements, Oxytocin API has been granted NMPA approval for commercial use as a chemical API in China. Furthermore, Degarelix Acetate API has received the FDA First Adequate Letter, enabling downstream formulation clients to proceed with their regulatory submissions. This product has already been referenced by a well-known U.S. pharmaceutical company.

   Patent applications   

JYMed has been granted a total of 91 patents, including more than 50 invention patents.

   Trademark & Copyright   

The company has filed over 60 trademark applications, including four trademarks in the European Union and three in the United States, and has obtained copyright registrations for four works.

    Certificate   

In 2011, JYMed was certified as a High-Tech Enterprise in Shenzhen.

In 2012, the company obtained certification as a National High-Tech Enterprise.

In 2018, JYMed was approved as the Guangdong Provincial Engineering Technology Research Center for Synthetic Peptide Innovative Drugs.

In 2020, the company was approved to establish the Guangdong Provincial Science and Technology Expert Workstation.

In 2021, JYMed was ranked among China’s Top 20 CDMO Enterprises.

In 2023, the company was recognized as a "Specialized and Innovative SME" in Shenzhen and listed as one of the Top 10 Innovation Platforms in Pingshan District. Additionally, its Semaglutide and Liraglutide products were awarded the title of Guangdong Province's High-Quality and High-Tech Products.JYMed's achievements in innovative peptide drug development have also been widely recognized, earning multiple awards in the Shenzhen Enterprise Innovation Records selection, including:The 21st Shenzhen Enterprise Innovation Record – Product R&D Innovation Project Award for "A Synthesis Method of Semaglutide",The 21st Shenzhen Enterprise Innovation Record (China Record) for "Alanine-Lysine-Glutamate Tripeptide Derivative and Its Applications",The 21st Shenzhen Enterprise Innovation Record (China Record) for "A Composition for Treating Rheumatoid Arthritis and Its Preparation Method",The 21st Shenzhen Enterprise Innovation Record (China Record) for "A Synthesis Method of Semaglutide".

In 2024, JYMed successfully renewed its certification as a National High-Tech Enterprise.